Blog
RSS FeedPosted by Michael Wonder on 20 Jul 2021
Pharma CEOs, lobbyists showered Democrat with cash after his attempt to torpedo Pelosi’s drug pricing bill
20 July 2021 - The very next day after Republican Scott Peters attempted to torpedo House Speaker Nancy Pelosi’s signature drug ...
Posted by Michael Wonder on 08 Jul 2021
House report: drug companies spent more on buybacks, dividends than research
8 July 2021 - House Democrats on Thursday released a report that found that the 14 leading drug companies paid ...
Posted by Michael Wonder on 28 Jun 2021
Success rate for marketing authorisation applications from SMEs doubles between 2016 and 2020
28 June 2021 - EMA has published today a report highlighting the Agency’s support for micro, small and medium sized ...
Posted by Michael Wonder on 06 Jun 2021
FDA’s decision on Biogen Alzheimer’s drug will be a watershed moment for the agency — and the biotech industry
4 June 2021 - In the coming days the FDA will make one of its most important — and controversial — ...
Posted by Michael Wonder on 23 May 2021
Congress loves a big pharma villain. But will that lead to any real policy changes on drug prices?
21 May 2021 - There's a funny cycle that resurfaces every now and then within the life sciences industry. ...
Posted by Michael Wonder on 20 May 2021
Katie Porter brings her whiteboard to accuse pharma CEO of inflating drug prices
19 May 2021 - Rep. Katie Porter (D-Calif.) went viral on social media after she brought back her signature whiteboard ...
Posted by Michael Wonder on 14 May 2021
Vaccine patent waivers deserve a warning label
13 May 2021 - The move to suspend patents on COVID-19 vaccines opens up a major risk to the way the ...
Posted by Michael Wonder on 11 May 2021
The pharma industry needs to measure patient experience from the patients’ perspectives
10 May 2021 - The relationship between clinical outcomes and the patient experience — the sum of all of interactions ...
Posted by Michael Wonder on 10 May 2021
The Government and Medicines Australia jointly agree to finalise patient centric strategic agreement after the Budget
8 May 2021 - Medicines Australia has been working closely with the Minister and his Department since last year to ...
Posted by Michael Wonder on 07 May 2021
Rather than turning its back on the QALY, pharma should collaborate on efforts to improve it
7 May 2021 - A key element in the long-simmering debate on reining in drug prices in the United States ...
Posted by Michael Wonder on 03 May 2021
Doubt over local mRNA plans as major companies pull out of Australia
3 May 2021 - Vaccine development experts say it will take at least $250 million plus the support of a ...
Posted by Michael Wonder on 03 May 2021
ALS groups to the FDA and drug sponsors: ‘We won’t be played again’
30 April 2021 - Working to improve the fight for therapies for amyotrophic lateral sclerosis (ALS, also known as Lou ...
Posted by Michael Wonder on 18 Apr 2021
Cancer researcher David Thomas says more should be done attract big pharma
18 April 2021 - A Garvan Institute cancer researcher says the government needs to attract big pharmaceutical companies to Australia ...
Posted by Michael Wonder on 14 Apr 2021
PhRMA's three part approach to build a better health care system
13 April 2021 - Our plan is based on three key pillars: ending the pandemic and building a more resilient system, ...
Posted by Michael Wonder on 25 Mar 2021
Taxpayers fund research and drug companies make a fortune
24 March 2021 - The pharmaceutical industry doesn’t want things to change, but Americans can have both lower prices and innovation. ...